Innovations in Heart Failure Pharmacotherapy

Heart failure (HF) remains a leading cause of morbidity and mortality, but recent innovations in pharmacotherapy are reshaping treatment paradigms. This session will highlight cutting-edge therapies for heart failure, focusing on new drug classes, including sodium-glucose co-transporter 2 (SGLT2) inhibitors, neprilysin inhibitors, and the expanding role of cardiac-specific gene therapies. Advances in personalized medicine, such as precision dosing based on genetic and biomarker profiles, will be discussed, along with novel combination therapies that address both symptoms and disease progression. The session will also explore the role of newer drugs in improving outcomes, reducing hospitalizations, and enhancing quality of life for heart failure patients.

    Related Conference of Innovations in Heart Failure Pharmacotherapy

    May 05-06, 2025

    19th World Drug Delivery Summit

    Vancouver, Canada
    June 16-17, 2025

    3rd Global Online Summit on Nanoscience and Nanotechnology

    Zurich, Switzerland
    June 23-24, 2025

    38th World Congress on Pharmacology

    Paris, France
    August 18-19, 2025

    40th World Congress on Pharmacology and Therapeutics

    Valencia, Spain
    September 22-23, 2025

    Pharma Biotech Expo

    Toronto, Canada
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 20-21, 2025

    21st Annual Congress on Pharmacology and Toxicology

    Aix-en-Provence, France
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 27-28, 2025

    13th International Conference on Clinical Trials

    Amsterdam, Netherlands
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland

    Innovations in Heart Failure Pharmacotherapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in